Yüklüyor......
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, ol...
Kaydedildi:
| Yayımlandı: | Br J Cancer |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5104889/ https://ncbi.nlm.nih.gov/pubmed/27736844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.311 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|